João Pedro Ferreira Selected Research

Eplerenone (Inspra)

4/2022	Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial.
1/2021	Head-to-head comparison of clustering methods for heterogeneous data: a simulation-driven benchmark.
1/2021	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial.
1/2021	Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction.
2/2020	Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials.
1/2020	Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial.
1/2020	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
1/2020	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial.
1/2020	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials.
1/2020	Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

João Pedro Ferreira Research Topics

Disease

116	Heart Failure 10/2022 - 10/2013
24	Myocardial Infarction 04/2022 - 02/2017
13	Fibrosis (Cirrhosis) 01/2022 - 01/2018
12	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2020
12	Stroke (Strokes) 10/2021 - 08/2016
10	Hypertension (High Blood Pressure) 11/2021 - 10/2017
9	Left Ventricular Dysfunction 04/2022 - 01/2018
8	Atrial Fibrillation 04/2022 - 08/2016
7	Inflammation (Inflammations) 01/2022 - 01/2019
6	Hyperkalemia 01/2022 - 01/2018
6	Acute Coronary Syndrome 01/2021 - 01/2018
6	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 05/2017
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2018
5	Respiratory Sounds (Crackle) 01/2022 - 05/2019
4	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2022 - 11/2019
4	Hypotension (Low Blood Pressure) 01/2021 - 01/2020
4	Chronic Renal Insufficiency 01/2021 - 11/2016
4	Hemorrhage 01/2021 - 08/2016
4	Diabetes Mellitus 01/2021 - 05/2017
3	Chronic Obstructive Pulmonary Disease (COPD) 10/2022 - 01/2020
3	Prediabetic State (Prediabetes) 08/2022 - 01/2021
3	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2016
3	Systolic Heart Failure 01/2021 - 01/2018
3	Renal Insufficiency (Renal Failure) 01/2021 - 01/2019
3	Albuminuria 01/2021 - 03/2014
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2021 - 01/2017
2	COVID-19 01/2022 - 02/2021
2	Neoplasms (Cancer) 01/2022 - 01/2019
2	Obesity 01/2022 - 01/2020
2	Gout 01/2022 - 01/2022
2	Isolated Systolic Hypertension 11/2021 - 07/2021
2	Anemia 01/2021 - 01/2018
2	ST Elevation Myocardial Infarction 02/2020 - 01/2018
2	Hypokalemia 01/2020 - 01/2020
1	Weight Gain 04/2022
1	Weight Loss (Weight Reduction) 04/2022
1	Hyponatremia 04/2022
1	Body Weight (Weight, Body) 04/2022
1	Hypernatremia 04/2022
1	Non-alcoholic Fatty Liver Disease 03/2022
1	Overweight 01/2022
1	Hypertrophy 01/2022
1	Necrosis 01/2022

Drug/Important Bio-Agent (IBA)

28	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2014
28	empagliflozinIBA 10/2022 - 01/2019
21	Spironolactone (Aldactone)FDA LinkGeneric 04/2022 - 03/2014
18	Eplerenone (Inspra)FDA LinkGeneric 04/2022 - 01/2018
17	Brain Natriuretic Peptide (Natrecor)FDA Link 10/2022 - 03/2014
15	Mineralocorticoid Receptor AntagonistsIBA 01/2022 - 01/2014
10	pro-brain natriuretic peptide (1-76)IBA 10/2022 - 01/2018
10	SodiumIBA 04/2022 - 06/2016
10	CreatinineIBA 02/2021 - 11/2016
9	DiureticsIBA 04/2022 - 10/2013
9	PotassiumIBA 01/2022 - 01/2018
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2019
8	Natriuretic PeptidesIBA 01/2022 - 12/2016
7	Pharmaceutical PreparationsIBA 03/2022 - 01/2011
7	CollagenIBA 01/2022 - 01/2018
6	AlbuminsIBA 10/2022 - 01/2018
6	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2020
5	Procollagen Type IIBA 01/2022 - 01/2019
5	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2020
5	alogliptinIBA 07/2021 - 01/2020
5	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 06/2021 - 01/2019
4	Insulin (Novolin)FDA Link 10/2022 - 04/2019
4	Troponin T (Troponin T1)IBA 10/2022 - 01/2014
4	Collagen Type III (Type III Collagen)IBA 01/2022 - 01/2019
4	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2021
4	procollagen Type III-N-terminal peptide (PIIP)IBA 01/2022 - 01/2019
4	Antihypertensive Agents (Antihypertensives)IBA 11/2021 - 05/2017
4	TroponinIBA 07/2021 - 01/2014
4	Angiotensin Receptor AntagonistsIBA 06/2021 - 01/2019
4	RivaroxabanIBA 01/2021 - 11/2019
4	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2021 - 01/2020
4	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2020 - 06/2016
3	Collagen Type I (Type I Collagen)IBA 01/2022 - 01/2021
3	Uric Acid (Urate)IBA 01/2022 - 10/2020
3	procollagen type I carboxy terminal peptide (PICP)IBA 01/2022 - 01/2019
3	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2021 - 01/2020
3	Hemoglobins (Hemoglobin)IBA 01/2021 - 04/2016
3	Valsartan (Vals)FDA Link 01/2021 - 01/2018
3	AldosteroneIBA 01/2020 - 01/2018
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2022
2	dapagliflozinIBA 11/2021 - 01/2020
2	omega-Chloroacetophenone (Mace)IBA 10/2021 - 02/2021
2	Biological ProductsIBA 02/2021 - 01/2020
2	SymportersIBA 01/2021 - 01/2021
2	Neprilysin (Neutral Endopeptidase)IBA 01/2021 - 01/2020
2	Losartan (Cozaar)FDA LinkGeneric 01/2021 - 01/2018
2	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 04/2015
2	Triglycerides (Triacylglycerol)IBA 11/2020 - 01/2018
2	CholesterolIBA 01/2020 - 01/2019
2	Carvedilol (Coreg)FDA LinkGeneric 01/2020 - 01/2018
2	AnticoagulantsIBA 11/2016 - 08/2016
1	MagnesiumIBA 02/2022
1	C-Reactive ProteinIBA 01/2022
1	Genetic Markers (Genetic Marker)IBA 01/2022
1	LigandsIBA 01/2022
1	Fenofibrate (CiL)FDA LinkGeneric 01/2022

Therapy/Procedure

40	Therapeutics 08/2022 - 10/2013